Yes, I had a huge one when IDMC recommended Argos discontinue the phase III trial. It is very painful and all personal investors on Argos feel the same way, I guess. I hope you guys have the chance to retrieve a loss if possible. NWBO will be probably worth betting on at this time.
1. The stock price is very cheap compared to its worth: now still cheaper than that of Argos
2. It has the innovative immunotherapy vaccine, DCVAX-L, whose phase III trial result is likely to be OK
3. The phase III trial interim data is expected to be announced around ASCO conference in June.
I know this is not enough answer for you, but I think you have ability to find the related article about NWBO.
Good Luck